Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingPhase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease

Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingPhase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme

Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingPhase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Treatment of Severe Aplastic Anemia by induction of mixed chimerism using CD4+ T cell depleted haploidentical donor stem cell transplant

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingTreatment of Severe Aplastic Anemia by induction of mixed chimerism using CD4+ T cell depleted haploidentical donor stem cell transplant

Evaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingEvaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV

A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingA Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA

TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingTACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingA Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1

Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingPhase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy

A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

• Post author:
• Post published:May 9, 2025
• Post category:

Continue ReadingA Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas